Chronic Obstructive Pulmonary Disease Clinical Trial
— CODEXOfficial title:
A Multi-centre, Randomised, Double-blind, Cross-over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort ®(Budesonide/Formoterol) 320/9μg One Inhalation Twice Daily Compared With Placebo and Oxis® 9μg One Inhalation Twice Daily in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this study is to investigate the effect on exercise tolerance, lung function and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic obstructive pulmonary disease.
Status | Completed |
Enrollment | 137 |
Est. completion date | August 2008 |
Est. primary completion date | August 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - >=40 years of age - diagnosed COPD with symptoms >= 2 years - pre-bronchodilatory FEV1 <=50% of PN Exclusion Criteria: - Current respiratory tract disorder other than COPD - history of asthma or rhinitis - significant or unstable cardiovascular disorder |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Research Site | Berlin | |
Germany | Research Site | Erfurt | |
Germany | Research Site | Fulda | |
Germany | Research Site | Furth | |
Germany | Research Site | Geesthacht | |
Germany | Research Site | Grobhansdorf | |
Germany | Research Site | Leipzig | |
Germany | Research Site | Neuruppin | |
Switzerland | Research Site | Basel | Basel Stadt |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Germany, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose | Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods. | Single measurement taken1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose | Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods. | Single measurement taken 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | Forced Expiratory Flow (FEV1) Pre-dose | The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment. | Pre-dose at the start of treatment and pre-dose after one week of treatment | No |
Secondary | Forced Vital Capacity (FVC) Pre-dose | The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment. | Pre-dose at the start of treatment and pre-dose after one week of treatment | No |
Secondary | Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment) | The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment. | Pre-dose at the start of treatment and pre-dose after one week of treatment | No |
Secondary | Peak Expiratory Flow (PEF) Before Morning Dose | The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period. | Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period | No |
Secondary | Sleep Score | The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (symptoms did not cause a sleep problem) to 4 (did not sleep at all due to symptoms). | Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period | No |
Secondary | Breathlessness Score | The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any difficulty in breathing) to 4 (almost constant difficulties in breathing). All patients with data from both periods are included. | Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period | No |
Secondary | Chest Tightness Score | The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any discomfort) to 4 (almost constant discomfort). | Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period | No |
Secondary | Cough Score | The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of coughing) to 4 (never free of need to cough). | Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period | No |
Secondary | Number of Inhalations of Reliever Medication | The change in average daily use for the run-in or wash-out period to the average daily use of the subsequent treatment period. | Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period | No |
Secondary | Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose | The Borg CR10 Scale consists of 10-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness. Patients are allowed to assign an even higher number depending on their perceived level of breathlessness). | Single measurement performed at rest prior to exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose | The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to >10 (absolute maximum breathing discomfort). | Single measurement performed after exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose | The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to >10 (absolute maximum breathing discomfort). | Single measurement performed at rest prior to exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose | The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to >10 (absolute maximum breathing discomfort). All patients with data are included. | Single measurement performed after exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 1hour post-dose at the end of each 1-week treatment period | No |
Secondary | Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period | No |
Secondary | Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 6 hous post-dose at the end of each 1-week treatment period | No |
Secondary | Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET) | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET | Treatment means from individual participant data. | Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period | No |
Secondary | SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score | Score from a questionnaire, with scores ranging form 0 (perfect health) to 100 (worst possible state). Includes all patients with data. | Single measurement taken at the end of each 1-week treatment period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|